TB-500 Research Guide
Recovery and tissue research peptide
TB-500 is a synthetic peptide based on a key active region of thymosin beta-4, a naturally occurring 43-amino-acid protein involved in cell migration, angiogenesis, and tissue repair. Its actin-sequestering activity and broad tissue distribution have made it a foundational research compound in models of muscle, tendon, cardiac, and corneal wound healing.
Contents
|
Tβ4 fragment From thymosin beta-4 |
Actin-sequestering Primary mechanism |
Multi-tissue Repair research |
What is TB-500?
TB-500 refers to a synthetic peptide that incorporates the LKKTETQ active sequence of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-binding protein found in nearly every mammalian cell type. The full thymosin beta-4 molecule is also studied in research, but TB-500 is the more commonly synthesized and characterized form for laboratory work.
Thymosin beta-4 itself was first isolated in 1981 by Allan Goldstein and colleagues from bovine thymus tissue. Its function as the principal actin-sequestering molecule in mammalian cells was characterized over the subsequent decade, opening up research into its role in cell motility, wound repair, and tissue regeneration.
Aeternum Labs supplies TB-500 as a lyophilized 5 mg vial, verified to 99%+ purity by HPLC with mass spectrometry sequence confirmation and LAL endotoxin screening. Every batch ships with a publicly published Certificate of Analysis tied to the lot number.
Mechanism of action
The defining mechanism of TB-500 is its high-affinity binding to G-actin (monomeric actin). By sequestering G-actin, the peptide regulates the available pool of actin monomers for filament polymerization, which directly affects cell shape, motility, and migration capacity at injury sites.
Beyond actin sequestration, thymosin beta-4 and its active fragments modulate inflammation, promote angiogenesis through VEGF-related pathways, and influence stem cell migration. Cardiac research has shown that thymosin beta-4 administration after myocardial infarction in animal models recruits epicardial progenitor cells to the injury site and improves contractile recovery.
Anti-inflammatory effects are mediated in part through downregulation of NF-kB signaling, which reduces pro-inflammatory cytokine release at injury sites. This mechanism contributes to the consistent finding of accelerated and lower-scarring tissue repair in TB-500 animal studies.
Research history
Thymosin beta-4 was first isolated from bovine thymus tissue in 1981. Its actin-sequestering function was characterized through the 1980s and early 1990s by multiple research groups, establishing it as the dominant cytoplasmic actin-binding protein in mammalian cells.
The TB-500 active fragment emerged as a synthesizable form for research applications in the late 1990s. Cardiac repair research using thymosin beta-4 administration began in the mid-2000s, with foundational papers by Bock-Marquette et al. demonstrating coronary epicardial cell migration and reduced infarct size in mouse models.
Subsequent research has expanded into corneal wound healing (multiple human clinical trials by RegeneRx Biopharmaceuticals using a synthetic Tβ4 formulation), neurological injury models, and musculoskeletal repair. The corneal program advanced through Phase 3 trials, providing the most extensive human safety data set for the molecule.
Half-life and pharmacokinetics
Plasma half-life of TB-500 is short (under one hour after subcutaneous administration in animal studies), but its tissue effects appear to extend beyond the immediate plasma window. The distribution profile favors injured tissue, with the peptide preferentially accumulating at sites of damage where actin dynamics are most active.
Subcutaneous and intramuscular administration routes are used in animal research with comparable bioavailability. Intravenous administration produces faster onset but is less commonly used in repair-focused study designs.
Typical research doses
Animal research dose ranges in the published thymosin beta-4 and TB-500 literature span approximately 10 microgram/kg to 10 mg/kg per administration. Cardiac repair studies typically use 150 microgram/kg administered intraperitoneally or subcutaneously.
Frequency in repair-focused study designs is most commonly twice weekly, leveraging the extended tissue effects of the peptide despite its short plasma half-life. Some protocols use daily dosing during the acute injury window followed by twice-weekly maintenance during recovery.
Compliance reminder
All dose ranges discussed are reported from peer-reviewed in vitro and animal research. They are not human-use dose recommendations.
Reconstitution protocol
Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.
Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.
Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.
For TB-500, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Each 0.1 mL contains 250 microgram, providing precise titration across the typical research dose range.
Storage and stability
Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.
Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.
Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.
Common stack pairings
TB-500 + BPC-157 (broad tissue and recovery research)
BPC-157’s VEGF and NOS pathway activity complements TB-500’s actin-sequestering and cell-migration mechanism. The combination is the most-studied dual peptide stack in tissue-repair literature, with published research across muscle, tendon, and CNS injury models.
TB-500 + GHK-Cu (skin and dermal repair)
GHK-Cu’s copper-binding and tissue remodeling activity adds a dermal-focused arm to TB-500’s broader tissue repair profile. This combination is researched in dermal wound and scar-modulation models.
How it compares
Compared to BPC-157: BPC-157 acts primarily through VEGF, nitric oxide synthase, and growth-factor pathways with broad oral bioavailability in animal models. TB-500 acts through actin sequestration and cell migration with primarily injectable administration. They are mechanistically complementary.
Compared to native thymosin beta-4 (full-length): The active fragment used in TB-500 captures the actin-binding activity but lacks some of the angiogenic and cardiac-specific effects of the full-length molecule. For research focused on actin dynamics and cell migration, TB-500 is sufficient. For studies of cardiac repair and angiogenesis, full-length Tβ4 may be preferable.
From the Aeternum library
TB-500 (5 mg)
- 99%+ purity verified by HPLC
- Mass spec sequence confirmation
- LAL endotoxin screening
- Full Certificate of Analysis published
- Lyophilized powder, 5 mg
Frequently asked questions
What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 (Tβ4) is the full 43-amino-acid native protein. TB-500 is a synthetic peptide based on the active LKKTETQ region of Tβ4. The active fragment captures the actin-sequestering and cell-migration activity but is less complete than the full-length molecule for studies of cardiac repair and angiogenesis.
Why is TB-500 commonly studied alongside BPC-157?
The two peptides act through mechanistically distinct pathways. BPC-157 drives VEGF and nitric oxide synthase activity, while TB-500 acts through actin sequestration and cell migration. The combination is the most-studied dual peptide stack in tissue-repair research, with published reports across muscle, tendon, and CNS injury models.
How is TB-500 typically administered in research?
Subcutaneous and intramuscular administration routes are used in most published animal research, with comparable bioavailability between the two. Intravenous administration produces faster onset but is less common in repair-focused study designs.
What dose ranges are used in published research?
Animal studies span approximately 10 microgram/kg to 10 mg/kg per administration. Cardiac research most commonly uses 150 microgram/kg intraperitoneally. Frequency is typically twice weekly for repair endpoints.
How long is reconstituted TB-500 stable?
Stored at 36–46°F (2–8°C) after reconstitution with bacteriostatic water, TB-500 is stable for approximately twenty-eight days. Sealed lyophilized vials at 0°F (−18°C) are stable up to twenty-four months.
References
- Bock-Marquette I, Saxena A, White MD, et al. (2004). Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. View source
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. View source
- Smart N, Risebro CA, Melville AA, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. View source
- Sosne G, Qiu P, Goldstein AL, Wheater M (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Articles in our research blog summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry and laboratory protocol design.
Related research
Category
Best peptides for tissue repair research →
Compare
BPC-157 vs TB-500 →
Pair with
BPC-157 research guide →
Pair with
GHK-Cu research guide →
Convenience
BPC-157 + TB-500 blend guide →
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.